Patents Assigned to Compugen Ltd.
  • PVRIG polypeptides and methods of treatment
    Patent number: 11795209
    Abstract: The present invention is directed to PVRIG polypeptides and their uses.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: October 24, 2023
    Assignee: COMPUGEN LTD.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Amir Toporik, Yossef Kliger, Ofer Levy, Arthur Machlenkin, Sergey Nemzer, Yair Benita, Amit Novik
  • Anti-PVRIG antibodies and methods of use
    Patent number: 11795220
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: October 24, 2023
    Assignee: COMPUGEN LTD.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
  • Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
    Patent number: 11701424
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: July 18, 2023
    Assignee: COMPUGEN LTD.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • ILDR2 antagonists and combinations thereof
    Patent number: 11655297
    Abstract: The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: May 23, 2023
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Compugen LTD.
    Inventors: Lars Röse, Uwe Gritzan, Julia Hütter, Spencer Liang, Andrew Pow, John Hunter, Ofer Levy, Ilan Vaknin
  • Anti-PVRIG antibodies and methods of use
    Patent number: 11623955
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: April 11, 2023
    Assignee: COMPUGEN LTD.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
  • COMBINATIONS OF ANTI-ILDR2 ANTIBODIES AND PD-1 ANTAGONISTS
    Publication number: 20220169736
    Abstract: The present invention relates to an anti-ILDR2 antibody, a fragment or derivative thereof, a modified antibody format, or an antibody mimetic for use in combination with a PD-1 antagonist in the treatment of cancer. Other aspects of the present invention relate to a combination comprising an anti-ILDR2 antibody and a PD-1 antagonist and the use of such combination as a medicament, as well as methods of treatment or prophylaxis of a cancer in a subject, comprising administering to said subject a therapeutically effective amount of the antibodies as described herein. Further, the present invention relates to a kit comprising anti-ILDR2 antibodies and PD-1 antagonists and optionally one or more further pharmaceutical agents.
    Type: Application
    Filed: April 6, 2020
    Publication date: June 2, 2022
    Applicants: Bayer Aktiengesellschaft, Compugen LTD.
    Inventors: Lars RÖSE, Uwe GRITZAN, Spencer LIANG, Andrew POW, John HUNTER, Ofer LEVY, Ilan VAKNIN
  • Triple combination antibody therapies
    Patent number: 11225523
    Abstract: The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: January 18, 2022
    Assignee: Compugen Ltd.
    Inventors: Spencer Liang, Ling Leung, Sarah Whelan, Maya Kotturi, Eran Ophir, Arthur Machlenkin, Zoya Alteber, Meir Azulay, Sandeep Kumar, Radhika Desai, Christopher Chan, Kathryn Logronio
  • Anti-PVRIG antibodies and methods of use
    Patent number: 11220542
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: January 11, 2022
    Assignee: Compugen Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
  • ILDR2 ANTAGONISTS AND COMBINATIONS THEREOF
    Publication number: 20200369769
    Abstract: The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.
    Type: Application
    Filed: November 28, 2018
    Publication date: November 26, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Compugen LTD.
    Inventors: Lars RÖSE, Uwe GRITZAN, Julia HÜTTER, Spencer LIANG, Andrew POW, John HUNTER, Ofer LEVY, Ilan VAKNIN
  • Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
    Patent number: 10751415
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: August 25, 2020
    Assignee: Compugen Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • PVRIG polypeptides and methods of treatment
    Patent number: 10550173
    Abstract: The present invention is directed to PVRIG polypeptides and their uses.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: February 4, 2020
    Assignee: Compugen, Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Amir Toporik, Yossef Kliger, Ofer Levy, Arthur Machlenkin, Sergey Nemzer, Yair Benita, Amit Novik
  • Anti-PVRIG antibodies and methods of use
    Patent number: 10351625
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: July 16, 2019
    Assignee: Compugen Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
  • Anti-PVRIG antibodies and methods of use
    Patent number: 10227408
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: March 12, 2019
    Assignee: Compugen Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
  • Anti-TIGIT anibodies, anti-PVRIG antibodies and combinations thereof
    Patent number: 10213505
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: February 26, 2019
    Assignee: Compugen Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
    Patent number: 10124061
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: November 13, 2018
    Assignee: Compugen Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
    Patent number: 10098934
    Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: October 16, 2018
    Assignee: COMPUGEN LTD
    Inventors: Zurit Levine, Amir Toporik, Amit Novik, Anat Cohen-Dayag, Avi Rosenberg, Cynthia Koifman, Dalit Landesman-Milo, Eve Montia, Galit Rotman, Liat Dassa, Marina Bubis, Merav Beiman, Ofer Levy, Sergey Nemzer, Shira Walach, Shirley Sameach- Greenwald, Tania Pergam, Yaron Kinar
  • POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS AND OTHER AUTOIMMUNE DISORDERS
    Publication number: 20170232062
    Abstract: This invention relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders.
    Type: Application
    Filed: April 30, 2016
    Publication date: August 17, 2017
    Applicant: Compugen Ltd.
    Inventors: Galit ROTMAN, Iris HECHT, Zurit LEVINE, Joseph R. PODOJIL, Stephen D. MILLER
  • C10RF32 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER
    Publication number: 20170233473
    Abstract: This invention relates to C1ORF32-specific antibodies, antibody fragments, alternative scaffolds, conjugates and compositions comprising same, for treatment of cancer.
    Type: Application
    Filed: February 28, 2017
    Publication date: August 17, 2017
    Applicant: Compugen Ltd.
    Inventors: Gady S. COJOCARU, Galit ROTMAN, Zurit LEVINE, Liat DASSA, Ofer LEVI, Raffaella BRIANTE, Shweta SINGH, Susan R. WATSON, Tania PERGAM
  • Anti-PVRIG antibodies and methods of use
    Patent number: 9714289
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: July 25, 2017
    Assignee: Compugen Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
  • C10RF32 antibodies, and uses thereof for treatment of cancer
    Patent number: 9617336
    Abstract: This invention relates to C1ORF32-specific antibodies, antibody fragments, alternative scaffolds, conjugates and compositions comprising same, for treatment of cancer.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: April 11, 2017
    Assignee: COMPUGEN LTD
    Inventors: Gady S. Cojocaru, Galit Rotman, Zurit Levine, Liat Dassa, Ofer Levi, Raffaella Briante, Shweta Singh, Susan R. Watson, Tania Pergam